|
|Section2= |Section3= }} Ataluren, formerly known as PTC124, is a pharmaceutical drug for the treatment of Duchenne muscular dystrophy and potentially other genetic disorders. It was designed by PTC Therapeutics and is sold under the trade name Translarna in the European Union. ==Medical uses== Ataluren has been tested on healthy humans and humans carrying genetic disorders caused by nonsense mutations, such as some people with cystic fibrosis and Duchenne muscular dystrophy. It is approved for the use in Duchenne in the European Union. 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Ataluren」の詳細全文を読む スポンサード リンク
|